Designs, tests and builds its own patient moving and handling equipment, supplied to the NHS, care providers and home care through large trade partners.
Based in the West Midlands, this company is a design-led manufacturer of medical furniture and patient handling equipment, working from a single leasehold site. It invents its own products, takes them through mechanical testing and clinical trials, and then builds them in-house. Nine products have been created from a blank sheet of paper in four years, all of the designs owned outright because the development was self-funded.
The lead product is a reclining chair now specified by most NHS trusts in the UK. Trusts will not accept an alternative to it, and the company holds a manufacturing exclusivity agreement on the product with a major UK hospital equipment framework holder. A recently launched tilt-in-space bed/chair has no competing product against it and took a first order of £400,000 with no marketing and no formal launch. The rest of the range covers bath lift mechanisms, highback chairs and sit-to-stand chairs, all of which have now completed development.
Sales run through three trade customers, each many times the size of the company. Ninety per cent of revenue is repeat and average order value is £30,000 to £50,000. Most product reaches the end user through the NHS rental market, so demand does not depend on trust capital budgets.
The company has never advertised, never employed a salesperson and has never sold outside the UK and Ireland. Everything has come by word-of-mouth from people who saw the products in use and made contact themselves. Approaches have arrived from six overseas markets in the last twelve months and none have been taken up. The order book stands at more than £550,000 and the owner is holding sales back because the current site cannot keep pace with demand.
Highlights -
Turnover of £578,336 in 2026, £500,548 in 2025 and £378,296 in 2024
Adjusted EBITDA of £21,498 in 2026, £213,159 in 2025 and £131,727 in 2024
The 2026 profit figure reflects a year in which most of the range was carried through development and clinical trials, a programme that is now complete
Management forecast for 2027 of £673,192 turnover and £498,624 adjusted EBITDA
Ninety per cent repeat revenue and an order book in excess of £550,000
For a buyer with manufacturing capacity, an export route or a sales function, this is a finished and approved product range with every commercial channel still unopened.
Opportunities -
International sales. Approaches have come from six overseas markets in the last twelve months and none has been pursued, with the bariatric range suiting the US market in particular
A first sales and marketing function. Nothing has ever been spent on winning work and there is no sales team
Manufacturing capacity. Demand already runs ahead of what the current site can supply
A proper launch for the products that finished development this year and have never been marketed
The development pipeline, including a modular healthcare equipment concept already generating weekly enquiries from the sector
Retaining the founder as a designer, which gives a buyer the future product pipeline as well as the current range.
Financial Profile
Turnover IRO - £578k in 2026.
Forecast 2027: IRO - £673k.
- 100% share capital.
- Leasehold premises available, pending agreement.
- Interested parties will be required to sign an NDA.
